Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction

18 May 2021

Abstract excerpt

Coronavirus disease 2019 (COVID-19) has spread globally as a severe pandemic, which is caused by a novel coronavirus named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). 1 COVID-19 is a serious threat to healthcare systems, economies, and is devastating to some populations, such as the elderly and those with comorbidities. It is likely to coexist with human beings for a long time. Unfortunately,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Bacteriophages and microbial interactions
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34006835
DOI: 10.1038/s41392-021-00619-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interactionPMID 34006835Read ↗

Inhibition of ACE2‐Spike Interaction by an ACE2 Binder Suppresses SARS‐CoV‐2 EntrySemantic proximity Read ↗

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and AntibodiesSemantic proximity Read ↗

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.Semantic proximity Read ↗

Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interactionSemantic proximity Read ↗

N-ferrocenylmethyl-Derivatives As Spike Glycoprotein Inhibitors Of SARS-CoV-2 Using In Silico ApproachesSemantic proximity Read ↗

Small-Molecule <i>In Vitro</i> Inhibitors of the Coronavirus Spike – ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2Semantic proximity Read ↗

GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.Semantic proximity Read ↗

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entrySemantic proximity Read ↗

Coronavirus (2019-nCoV) Deactivation via Spike Glycoprotein Shielding by Old Drugs, Bioinformatic StudySemantic proximity Read ↗

Development of an in Vitro Model to Investigate the Regulation of ACE2 Expression and its Correlation with ACE2-Mediated Viral EntrySemantic proximity Read ↗

Epigallocatechin Gallate from Green Tea Effectively Blocks Infection of SARS-CoV-2 and New Variants by Inhibiting Spike Binding to ACE2 ReceptorSemantic proximity Read ↗

Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory EffectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.